Handelsavisen
prelaunch
Companies ›Healthcare ›IMCR.O
IM
IMCR.O — NASDAQ Biotechnology

Imcr.O

$32,22
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
0,00 %
Op margin
-11,3 %
ROE
-9,3 %
Net margin
-8,9 %
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$33,42
Open
$33,41
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About

Immunocore Holdings PLC is a biotechnology company operating within the Health Care sector, though specific product or revenue-generating activities are not detailed in the available data.

Business. Immunocore Holdings PLC is a biotechnology company operating within the Health Care sector, though specific product or revenue-generating activities are not detailed in the available data.

Classification85 %
SectorHealth Care
Industry groupBiotechnology
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
T. Rowe Price Investment Management, Inc.
largest disclosed fund holder
Profitability→
-9,3 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning IMCR.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to IMCR.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Immunocore Holdings PLC is a biotechnology company operating within the Health Care sector, though specific product or revenue-generating activities are not detailed in the available data.

    Classification85 %
    SectorHealth Care
    Industry groupBiotechnology
    AI synthesis
    GENERATED

    (a) Capital structure and liquidity: The company maintains a conservative balance sheet with $467.7 million in cash and equivalents against total liabilities of $686.2 million. Debt-to-equity is 0.0, indicating no interest-bearing debt, while total equity stands at $381.0 million. Liquidity risk is assessed as low, supported by the substantial cash reserve relative to operating needs.

    (b) Profitability and returns: The firm is not yet profitable, reporting a net loss of $35.5 million and an operating loss of $45.4 million on revenue of $400.0 million. Return on equity is -9.32% and return on assets is -3.33%, reflecting the pre-profitability stage typical of growth-stage biotechnology firms.

    Key takeaways
    • Strong liquidity position with $467.7 million in cash and zero debt.
    • Pre-profitability status with a net loss of $35.5 million on $400.0 million revenue.
    • Low dilution and liquidity risk flags according to internal assessment.
    • Lack of segment, geographic, or historical trend data limits deeper fundamental analysis.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $32,22
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $381.0M
    Net cashⓘ
    $467.7M
    Current ratioⓘ
    —
    Debt / equityⓘ
    —
    ROAⓘ
    -3.3%
    ROEⓘ
    -9.3%
    Cash conversionⓘ
    30.0%
    CapEx / revenueⓘ
    1.1%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution15 analysts
    Strong buy4
    Buy7
    Hold4
    Sell0
    Strong sell0
    12-month price target$66,85 · Median $73,00
    Low $34,00High $100,00
    Operating income · consensus-9,2M USD
    EPS surprise
    −609,9 %
    reported vs consensus · miss
    Revenue surprise
    −10,4 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$34,00
    Mean$66,85
    Median$73,00
    High$100,00
    Spot$32,22
    +107.5 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-11,3 %Above median
    Net Margin-8,9 %Above median
    ROE-9,3 %Above median
    Capex / Rev1,1 %Above median
    D/E0,00Above median
    Cash Conv0,30Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 507 175 sh15 exercises · 12 grants11 insiders
    • Bell John IrvingDirector · Share Option (Right to Buy) → Ordinary SharesAcquired 27 492 @ $28,52grant · 2026-05-27
    • Pao WilliamDirector · Share Option (Right to Buy) → Ordinary SharesAcquired 27 492 @ $28,52grant · 2026-05-27
    • Peterson KristineDirector · Share Option (Right to Buy) → Ordinary SharesAcquired 27 492 @ $28,52grant · 2026-05-27
    • Ratcliffe Peter JohnDirector · Share Option (Right to Buy) → Ordinary SharesAcquired 27 492 @ $28,52grant · 2026-05-27
    • Kaul SiddharthDirector · Share Option (Right to Buy) → Ordinary SharesAcquired 27 492 @ $28,52grant · 2026-05-27
    • Herbst Roy StevenDirector · Share Option (Right to Buy) → Ordinary SharesAcquired 27 492 @ $28,52grant · 2026-05-27
    • GOLL JOHNSVP, FINANCE & CAO · Restricted Share Units → Ordinary SharesDisposed 1 351exercise · 2026-02-17
    • Jallal BahijaDirector, CHIEF EXECUTIVE OFFICER · Employee Share Option (Right to Buy) → Ordinary SharesAcquired 395 066 @ $32,38grant · 2026-02-17
    • Jallal BahijaDirector, CHIEF EXECUTIVE OFFICER · Restricted Share Units → Ordinary SharesAcquired 88 573grant · 2026-02-17
    • GOLL JOHNSVP, FINANCE & CAO · Restricted Share Units → Ordinary SharesAcquired 7 411grant · 2026-02-17
    • Jallal BahijaDirector, CHIEF EXECUTIVE OFFICER · Restricted Share Units → Ordinary SharesDisposed 23 817exercise · 2026-02-17
    • Coy Travis AlanChief Financial Officer · Employee Share Option (Right to Buy) → Ordinary SharesAcquired 95 637 @ $32,38grant · 2026-02-17
    • Coy Travis AlanChief Financial Officer · Restricted Share Units → Ordinary SharesAcquired 33 353grant · 2026-02-17
    • GOLL JOHNSVP, FINANCE & CAO · Employee Share Option (Right to Buy) → Ordinary SharesAcquired 21 252 @ $32,38grant · 2026-02-17
    • Berman David MHEAD OF R&D · Restricted Share Units → Ordinary SharesDisposed 11 824exercise · 2026-02-17
    • St Leger Tina AmberCHIEF HR OFFICER · Restricted Share Units → Ordinary SharesDisposed 2 119exercise · 2026-02-17
    • Berman David MHEAD OF R&D · Employee Share Option (Right to Buy) → Ordinary SharesDisposed 572 @ $17,46exercise · 2025-12-05
    • Berman David MHEAD OF R&D · Employee Share Option (Right to Buy) → Ordinary SharesDisposed 31 341 @ $17,46exercise · 2025-12-04
    • Berman David MHEAD OF R&D · Employee Share Option (Right to Buy) → Ordinary SharesDisposed 5 521 @ $17,46exercise · 2025-11-28
    • Berman David MHEAD OF R&D · Employee Share Option (Right to Buy) → Ordinary SharesDisposed 69 404 @ $17,46exercise · 2025-11-26
    • Berman David MHEAD OF R&D · Employee Share Option (Right to Buy) → Ordinary SharesDisposed 18 020 @ $17,46exercise · 2025-11-25
    • Berman David MHEAD OF R&D · Employee Share Option (Right to Buy) → Ordinary SharesDisposed 100 @ $17,46exercise · 2025-11-24
    • Berman David MHEAD OF R&D · Employee Share Option (Right to Buy) → Ordinary SharesDisposed 61 849 @ $17,46exercise · 2025-09-30
    • Berman David MHEAD OF R&D · Employee Share Option (Right to Buy) → Ordinary SharesDisposed 200 @ $17,46exercise · 2025-09-15
    • Berman David MHEAD OF R&D · Employee Share Option (Right to Buy) → Ordinary SharesDisposed 22 532 @ $17,46exercise · 2025-09-12

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    • Reference data
    How metrics are computed
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Capex To Revenue
      capital_expenditure / revenue
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    Source documents
    • Immunocore Holdings plc Market data — financials · 2026-07-30
    • reconciler_enqueue (reconciler) on IMCR.O · 2026-07-30

    Ownership & reference

    Top holders

    • T. Rowe Price Investment Management, Inc.Investment Managers · as of 2026-03-310,04 %$0M
    • JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,01 %$18M
    • Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,01 %$16M
    • FMR LLCInstitutional Investor · as of 2026-03-310,01 %$146M
    • MASSACHUSETTS FINANCIAL SERVICES CO /MA/Institutional Investor · as of 2026-03-310,00 %$12M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$30M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$10M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$4M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$1M

    Leadership

    • Bahija JallalChief Executive Officer, Executive Director

    Insider activity

    Net selling0 buys · 17 sellsnet -$10,4M4 insiders · last 365d
    • Berman David MHEAD OF R&D · Ordinary SharesSold 5 965 @ $32,35$193K · 2026-02-18
    • Jallal BahijaDirector, CHIEF EXECUTIVE OFFICER · Ordinary SharesSold 11 474 @ $32,35$371K · 2026-02-18
    • GOLL JOHNSVP, FINANCE & CAO · Ordinary SharesSold 698 @ $32,35$23K · 2026-02-18
    • St Leger Tina AmberCHIEF HR OFFICER · Ordinary SharesSold 1 000 @ $32,35$32K · 2026-02-18
    • St Leger Tina AmberCHIEF HR OFFICER · Ordinary SharesOther 2 119 · 2026-02-17
    • GOLL JOHNSVP, FINANCE & CAO · Ordinary SharesOther 1 351 · 2026-02-17
    • Berman David MHEAD OF R&D · Ordinary SharesOther 11 824 · 2026-02-17
    • Jallal BahijaDirector, CHIEF EXECUTIVE OFFICER · Ordinary SharesOther 23 817 · 2026-02-17
    • Berman David MHEAD OF R&D · Ordinary SharesSold 572 @ $40,14$23K · 2025-12-05
    • Berman David MHEAD OF R&D · Ordinary SharesOther 572 @ $17,46$10K · 2025-12-05
    • Berman David MHEAD OF R&D · Ordinary SharesOther 31 341 @ $17,46$547K · 2025-12-04
    • Berman David MHEAD OF R&D · Ordinary SharesSold 31 341 @ $40,26$1,3M · 2025-12-04
    • Berman David MHEAD OF R&D · Ordinary SharesSold 5 521 @ $40,09$221K · 2025-11-28
    • Berman David MHEAD OF R&D · Ordinary SharesOther 5 521 @ $17,46$96K · 2025-11-28
    • Berman David MHEAD OF R&D · Ordinary SharesSold 69 404 @ $40,12$2,8M · 2025-11-26
    • Berman David MHEAD OF R&D · Ordinary SharesOther 69 404 @ $17,46$1,2M · 2025-11-26
    • Berman David MHEAD OF R&D · Ordinary SharesOther 18 020 @ $17,46$315K · 2025-11-25
    • Berman David MHEAD OF R&D · Ordinary SharesSold 18 020 @ $40,03$721K · 2025-11-25
    • Berman David MHEAD OF R&D · Ordinary SharesOther 100 @ $17,46$2K · 2025-11-24
    • Berman David MHEAD OF R&D · Ordinary SharesSold 100 @ $40,00$4K · 2025-11-24
    • Berman David MHEAD OF R&D · Ordinary SharesOther 61 849 @ $17,46$1,1M · 2025-09-30
    • Berman David MHEAD OF R&D · Ordinary SharesSold 61 849 @ $35,23$2,2M · 2025-09-30
    • Berman David MHEAD OF R&D · Ordinary SharesOther 200 @ $17,46$3K · 2025-09-15
    • Berman David MHEAD OF R&D · Ordinary SharesSold 200 @ $35,01$7K · 2025-09-15
    • Berman David MHEAD OF R&D · Ordinary SharesOther 22 532 @ $17,46$393K · 2025-09-12

    Short positioning

    8.9Mshares short-0.6% vs prior
    12.63days to cover
    12.0%short of daily vol
    15fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    IMCR.OCanonical
    NASDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    • Cost of revenue (annual): USD 5.09MUnknown
    • Revenue (annual): USD 400.02MUnknown
    • Operating income (annual): USD -45.35MUnknown
    • Current assets (annual): USD 996.74MUnknown
    • Operating cash flow (annual): USD -10.71MUnknown
    • Total assets (annual): USD 1.07BUnknown
    • EPS (diluted) (annual): USD-PER-SHARES -1Unknown
    • Total liabilities (annual): USD 686.24MUnknown
    • EPS (basic) (annual): USD-PER-SHARES -1Unknown
    • Capex (annual): USD 4.34MUnknown
    • Current liabilities (annual): USD 246.7MUnknown
    • Shares outstanding (annual): 50.69MUnknown
    • Cash & equivalents (annual): USD 467.71MUnknown
    • Pre-tax income (annual): USD -19.1MUnknown
    • Net income (annual): USD -35.51MUnknown
    • R&D expense (annual): USD 274.87MUnknown
    • Shareholders' equity (annual): USD 381.03MUnknown
    • Total liabilities (annual): USD 648.79MUnknown
    • Total assets (annual): USD 1.01BUnknown
    • Net income (annual): USD -51.09MUnknown
    • Pre-tax income (annual): USD -52.94MUnknown
    • R&D expense (annual): USD 222.15MUnknown
    • Cash & equivalents (annual): USD 455.73MUnknown
    • Shareholders' equity (annual): USD 360.72MUnknown
    Showing 24 of 32 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-05-27 00:00 UTCINSIDER6 insider transactions — 2026-05 6 derivative
    2026-05-27 00:00 UTCINSIDER6 insider transactions — 2026-05 6 derivative
    2026-05-27FILING8-K filing →
    2026-05-27INSIDERBell John Irving acquired 27.5k sh Share Option (Right to Buy) — Director
    2026-05-27INSIDERRatcliffe Peter John acquired 27.5k sh Share Option (Right to Buy) — Director
    2026-05-27INSIDERPeterson Kristine acquired 27.5k sh Share Option (Right to Buy) — Director
    2026-05-27INSIDERPao William acquired 27.5k sh Share Option (Right to Buy) — Director
    2026-05-27INSIDERKaul Siddharth acquired 27.5k sh Share Option (Right to Buy) — Director
    2026-05-27INSIDERHerbst Roy Steven acquired 27.5k sh Share Option (Right to Buy) — Director
    2026-05-06FILING8-K filing →
    2026-05-06FILING10-Q filing →
    2026-04-16FILINGDEF 14A filing →
    2026-02-25FILING8-K filing →
    2026-02-25FILING10-K filing →
    2026-02-18 00:00 UTCINSIDER18 insider transactions — 2026-02 · net sell $619k 10 derivative
    2026-02-18 00:00 UTCINSIDER18 insider transactions — 2026-02 · net sell $619k 10 derivative
    2026-02-18INSIDERBerman David M sold 6.0k sh Ordinary Shares — HEAD OF R&D ~$193k
    2026-02-18INSIDERJallal Bahija sold 11.5k sh Ordinary Shares — Director, CHIEF EXECUTIVE OFFICER ~$371k
    2026-02-18INSIDERGOLL JOHN sold 698 sh Ordinary Shares — SVP, FINANCE & CAO ~$23k
    2026-02-18INSIDERSt Leger Tina Amber sold 1.0k sh Ordinary Shares — CHIEF HR OFFICER ~$32k
    2026-02-17INSIDERSt Leger Tina Amber transacted 2.1k sh Ordinary Shares — CHIEF HR OFFICER
    2026-02-17INSIDERGOLL JOHN transacted 1.4k sh Ordinary Shares — SVP, FINANCE & CAO
    2026-02-17INSIDERBerman David M transacted 11.8k sh Ordinary Shares — HEAD OF R&D
    2026-02-17INSIDERJallal Bahija transacted 23.8k sh Ordinary Shares — Director, CHIEF EXECUTIVE OFFICER
    2026-02-17INSIDERJallal Bahija acquired 395.1k sh Employee Share Option (Right to Buy) — Director, CHIEF EXECUTIVE OFFICER
    2026-02-17INSIDERGOLL JOHN disposed of 1.4k sh Restricted Share Units — SVP, FINANCE & CAO
    2026-02-17INSIDERGOLL JOHN acquired 7.4k sh Restricted Share Units — SVP, FINANCE & CAO
    2026-02-17INSIDERGOLL JOHN acquired 21.3k sh Employee Share Option (Right to Buy) — SVP, FINANCE & CAO
    2026-02-17INSIDERJallal Bahija disposed of 23.8k sh Restricted Share Units — Director, CHIEF EXECUTIVE OFFICER
    2026-02-17INSIDERJallal Bahija acquired 88.6k sh Restricted Share Units — Director, CHIEF EXECUTIVE OFFICER
    2026-02-17INSIDERCoy Travis Alan acquired 33.4k sh Restricted Share Units — Chief Financial Officer
    2026-02-17INSIDERCoy Travis Alan acquired 95.6k sh Employee Share Option (Right to Buy) — Chief Financial Officer
    2026-02-17INSIDERBerman David M disposed of 11.8k sh Restricted Share Units — HEAD OF R&D
    2026-02-17INSIDERSt Leger Tina Amber disposed of 2.1k sh Restricted Share Units — CHIEF HR OFFICER
    2026-01-30FILING8-K filing →
    2026-01-09FILING8-K filing →
    2025-12-05 00:00 UTCINSIDER6 insider transactions — 2025-12 · net sell $728k 2 derivative
    2025-12-05 00:00 UTCINSIDER6 insider transactions — 2025-12 · net sell $728k 2 derivative
    2025-12-05INSIDERBerman David M sold 572 sh Ordinary Shares — HEAD OF R&D ~$23k
    Showing the 40 most recent of 61 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage